JohnEFitzgeraldMD
Pulmonology • Dallas, TXCritical Care Medicine, Interstitial Lung Diseases
Professor of Medicine
Dr. Fitzgerald is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-6616Fax+1 214-645-6020
Summary
- Dr. John Fitzgerald is a pulmonologist in Dallas, TX and is affiliated with multiple hospitals in the area, including University of Texas Southwestern Medical Center, Parkland Health & Hospital System, and William P. Clements, Jr. University Hospital. He received his medical degree from Washington University School of Medicine in St. Louis and has been in practice 28 years. He specializes in interstitial lung disease and is experienced in connective tissue disease, vasculitis, bronchiolitis, sarcoidosis, and critical care medicine.
Education & Training
University of ColoradoFellowship, Pulmonary Disease and Critical Care Medicine, 1992 - 1995
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1989 - 1992
Washington University in St. Louis School of MedicineClass of 1989
Certifications & Licensure
TX State Medical License 1990 - 2026- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Best Doctors in Dallas "D" Magazine, 2005-2021
- Best Doctors in America Best Doctors, 2011-2020
- America's Top Physicians Consumers' Research Council of America, 2009-2020
- Join now to see all
Clinical Trials
- Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Start of enrollment: 2009 Oct 01
- AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis Start of enrollment: 2009 Oct 01
- Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
Publications & Presentations
PubMed
- 47 citationsCombination therapy with oral treprostinil for pulmonary arterial hypertension: A double-blind placebo-controlled clinical trialR. James White, Carlos Jerjes-Sánchez, Gisela Martina Bohns Meyer, Tomas Pulido, Pablo Sepúlveda
American Journal of Respiratory and Critical Care Medicine. 2020-03-15 - 315 citationsExome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shorteningBridget D. Stuart, Jungmin Choi, Samir Zaidi, Chao Xing, Brody Holohan
Nature Genetics. 2015-05-01 - 32 citationsThe Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes.Joao A. de Andrade, Marvin I. Schwarz, Harold R. Collard, Tedryl Gentry-Bumpass, Thomas V. Colby
Chest. 2015-10-01
Professional Memberships
- Fellow
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
